NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Forecast, Price & News $58.47 +1.86 (+3.29%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$56.57▼$59.1550-Day Range$42.20▼$60.0352-Week Range$37.82▼$79.40Volume411,762 shsAverage Volume581,670 shsMarket Capitalization$3.54 billionP/E RatioN/ADividend YieldN/APrice Target$73.11 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Blueprint Medicines MarketRank™ ForecastAnalyst RatingHold2.44 Rating ScoreUpside/Downside28.1% Upside$74.89 Price TargetShort InterestHealthy5.92% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.04Based on 17 Articles This WeekInsider TradingSelling Shares$120,102 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($9.55) to ($7.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector347th out of 987 stocksPharmaceutical Preparations Industry156th out of 477 stocks 4.3 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Buy. The company's average rating score is 2.53, and is based on 8 buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.89, Blueprint Medicines has a forecasted upside of 28.1% from its current price of $58.47.Amount of Analyst CoverageBlueprint Medicines has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.92% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Blueprint Medicines has recently decreased by 5.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPMC. Previous Next 1.6 News and Social Media Coverage News SentimentBlueprint Medicines has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Blueprint Medicines this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $120,102.00 in company stock.Percentage Held by InsidersOnly 3.88% of the stock of Blueprint Medicines is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($9.55) to ($7.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 6.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Blueprint Medicines (NASDAQ:BPMC) StockBlueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.Read More Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Stock News HeadlinesJune 9, 2023 | finance.yahoo.comBlueprint Medicines (NASDAQ:BPMC) investors are sitting on a loss of 24% if they invested five years agoJune 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC) and Relay Therapeutics (RLAY)June 9, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.June 7, 2023 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Shares Gap Down to $58.22June 6, 2023 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Downgraded to "Underperform" at SVB LeerinkJune 5, 2023 | msn.comSVB Leerink Downgrades Blueprint Medicines (BPMC)June 5, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Blueprint Medicines (BPMC) and Taro Pharmaceutical (TARO)June 5, 2023 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by SVB SecuritiesJune 9, 2023 | Behind the Markets (Ad)Here's something only a handful of people knowOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...June 5, 2023 | americanbankingnews.comHead-To-Head Comparison: Blueprint Medicines (NASDAQ:BPMC) and Hypera (OTCMKTS:HYPMY)June 4, 2023 | finance.yahoo.comThis Biotech Could Soon Go Parabolic, But Should You Buy It?June 3, 2023 | finance.yahoo.comBlueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual MeetingJune 1, 2023 | americanbankingnews.comBlueprint Medicines Co. (NASDAQ:BPMC) Short Interest UpdateMay 30, 2023 | americanbankingnews.comQ3 2023 EPS Estimates for Blueprint Medicines Co. (NASDAQ:BPMC) Boosted by WedbushMay 27, 2023 | americanbankingnews.comBlueprint Medicines Co. (NASDAQ:BPMC) Forecasted to Post Q2 2023 Earnings of ($2.31) Per ShareMay 27, 2023 | americanbankingnews.comWedbush Weighs in on Blueprint Medicines Co.'s Q2 2023 Earnings (NASDAQ:BPMC)May 26, 2023 | americanbankingnews.comGuggenheim Boosts Blueprint Medicines (NASDAQ:BPMC) Price Target to $82.00May 25, 2023 | americanbankingnews.comFY2024 Earnings Forecast for Blueprint Medicines Co. (NASDAQ:BPMC) Issued By SVB LeerinkMay 25, 2023 | americanbankingnews.comHC Wainwright Boosts Blueprint Medicines (NASDAQ:BPMC) Price Target to $85.00May 25, 2023 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Price Target Increased to $46.00 by Analysts at BarclaysMay 25, 2023 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Shares Gap Up After Analyst UpgradeMay 23, 2023 | markets.businessinsider.comAnalyst Expectations for Blueprint Medicines's FutureMay 23, 2023 | msn.comWedbush Reiterates Blueprint Medicines (BPMC) Outperform RecommendationMay 23, 2023 | markets.businessinsider.comBlueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's FutureMay 23, 2023 | finance.yahoo.comNEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic MastocytosisMay 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Biogen (BIIB), Blueprint Medicines (BPMC) and Cerevel Therapeutics Holdings (CERE)May 23, 2023 | markets.businessinsider.comBlueprint Medicines (BPMC) Gets a Buy from JMP SecuritiesSee More Headlines BPMC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMC Company Calendar Last Earnings5/04/2023Today6/09/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPMC CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees495Year Founded2011Price Target and Rating Average Stock Price Forecast$74.89 High Stock Price Forecast$114.00 Low Stock Price Forecast$38.00 Forecasted Upside/Downside+25.0%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($9.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-557,520,000.00 Net Margins-284.02% Pretax Margin-281.29% Return on Equity-100.31% Return on Assets-44.52% Debt Debt-to-Equity Ratio0.29 Current Ratio5.21 Quick Ratio5.11 Sales & Book Value Annual Sales$204.04 million Price / Sales17.33 Cash FlowN/A Price / Cash FlowN/A Book Value$8.60 per share Price / Book6.80Miscellaneous Outstanding Shares60,470,000Free Float58,121,000Market Cap$3.54 billion OptionableOptionable Beta0.71 Social Links Key ExecutivesKathryn HavilandPresident, Chief Executive Officer & DirectorChristina RossiChief Operating OfficerMichael LandsittelChief Financial OfficerChristopher K. MurraySenior Vice President-Technical OperationsJanet LoesbergSenior Vice President-Global Medical AffairsKey CompetitorsReata PharmaceuticalsNASDAQ:RETAAmicus TherapeuticsNASDAQ:FOLDMaravai LifeSciencesNASDAQ:MRVIImmunoGenNASDAQ:IMGNCytokineticsNASDAQ:CYTKView All CompetitorsInsiders & InstitutionsPercy H CarterSold 2,307 sharesTotal: $120,102.42 ($52.06/share)Macquarie Group Ltd.Bought 186,636 shares on 6/1/2023Ownership: 2.476%ProShare Advisors LLCSold 2,352 shares on 5/26/2023Ownership: 0.019%Capital Impact Advisors LLCBought 2,801 shares on 5/23/2023Ownership: 0.017%Ameriprise Financial Inc.Sold 6,598 shares on 5/22/2023Ownership: 0.094%View All Insider TransactionsView All Institutional Transactions BPMC Stock - Frequently Asked Questions Should I buy or sell Blueprint Medicines stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 2 sell ratings, 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPMC shares. View BPMC analyst ratings or view top-rated stocks. What is Blueprint Medicines' stock price forecast for 2023? 15 analysts have issued twelve-month price targets for Blueprint Medicines' stock. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they expect the company's stock price to reach $74.89 in the next year. This suggests a possible upside of 28.1% from the stock's current price. View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts. How have BPMC shares performed in 2023? Blueprint Medicines' stock was trading at $43.81 at the beginning of the year. Since then, BPMC stock has increased by 33.5% and is now trading at $58.47. View the best growth stocks for 2023 here. When is Blueprint Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our BPMC earnings forecast. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) issued its earnings results on Thursday, May, 4th. The biotechnology company reported ($2.15) earnings per share for the quarter, beating the consensus estimate of ($2.66) by $0.51. The biotechnology company earned $63.29 million during the quarter, compared to the consensus estimate of $41.85 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 100.31% and a negative net margin of 284.02%. The company's revenue was up .9% on a year-over-year basis. During the same period last year, the company posted ($1.79) earnings per share. What ETFs hold Blueprint Medicines' stock? ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), BlackRock Future Health ETF (BMED), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC). What is Kate Haviland's approval rating as Blueprint Medicines' CEO? 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR). When did Blueprint Medicines IPO? (BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Blueprint Medicines' stock symbol? Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC." Who are Blueprint Medicines' major shareholders? Blueprint Medicines' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.59%), BlackRock Inc. (10.95%), Wellington Management Group LLP (8.50%), Price T Rowe Associates Inc. MD (8.18%), State Street Corp (4.56%) and JPMorgan Chase & Co. (2.57%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Nicholas Lydon, Percy H Carter and Tracey L Mccain. View institutional ownership trends. How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Blueprint Medicines' stock price today? One share of BPMC stock can currently be purchased for approximately $58.47. How much money does Blueprint Medicines make? Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.54 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis. How many employees does Blueprint Medicines have? The company employs 495 workers across the globe. How can I contact Blueprint Medicines? Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com. This page (NASDAQ:BPMC) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.